Company: BLCO
Filing Date: 2025-07-30
Form Type: 10-Q
Source: 0001860742-25-000018
Chunk: 128

Company: Bausch & Lomb Corp
Filing Date: 2025-07-30
Form: 10-Q
Item: Item 2
Chunk 128
---
 2024 were as follows:Six Months Ended June 30,20252024(in millions)AmountPct.AmountPct.Gross product sales$3,936 100.0 %$3,606 100.0 %Provisions to reduce gross product sales to net product salesDiscounts and allowances225 5.70 %208 5.80 %Returns32 0.80 %48 1.30 %Rebates932 23.70 %688 19.10 %Chargebacks295 7.50 %318 8.80 %Distribution fees47 1.20 %37 1.00 %Total provisions1,531 38.90 %1,299 36.00 %Net product sales2,405 61.10 %2,307 64.00 %Other revenues10 8 Revenues$2,415 $2,315 Cash discounts and allowances, returns, rebates, chargebacks and distribution fees as a percentage of gross product sales were 38.9% and 36.0% for the six months ended June 30, 2025 and 2024, respectively, an increase of 2.9% percentage points, and is primarily attributable to the increase in rebates from our dry eye portfolio, including XIIDRA® and MIEBO®.Operating ExpensesCost of Goods Sold (exclusive of amortization and impairments of intangible assets)Cost of goods sold was $1,004 million and $905 million for the six months ended June 30, 2025 and 2024, respectively, an increase of $99 million, or 11%. The increase was primarily driven by: (i) higher volumes and (ii) higher manufacturing variances, which include an inventory reserve related to the voluntary recall of certain enVista IOL products.Contribution (product sales revenue less cost of goods sold, exclusive of amortization and impairments of intangible assets) decreased by $1 million, primarily driven by: (i) higher manufacturing variances, including that related to the voluntary recall of certain enVista IOL products and (ii) product mix.Cost of goods sold as a percentage of Product sales was 41.7% and 39.2% for the six months ended June 30, 2025 and 2024, respectively. The unfavorable change was driven by product mix and the overall impact